News

Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.

The PARP inhibitor olaparib (Lynparza) was shown to reduce the risk of disease progression by 42% compared to standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer.

A recent study has found that a topical nail bed balm may be effective in preventing and mitigating nail damage, a common adverse effect from taxane chemotherapy.

By developing a training program, nurses in radiation at Johns Hopkins Hospital were able to eliminate the use of anasthesia for pediatric patients.

The novel psychological intervention, called CALM, has been shown to alleviate the distress of patients with advanced cancer.

The incidence of prostate cancer is 60% in black men in the US than in white men, and they are twice as likely to die from the disease.

As the intensity of treatments for childhood cancer drop, so does the rate of severe long-term side effects in these patients.

Patients new diagnosed with cancer were able to improve quality of life and distress by through a web-based stress management program.

A recent study presented at the 2017 ASCO Annual Meeting found that breast cancer survivors who became pregnant had no greater risk of recurrence or death than women who underwent breast cancer treatment but did not become pregnant.

As presented at the 2017 ASCO Annual Meeting, adding abemaciclib to fulvestrant can reduce the risk of disease progression or death by 45% compared to fulvestrant alone in pretreated patients with HR+/HER2-negative breast cancer.

According to findings presented at the 2017 ASCO Annual Meeting, patients with low-risk advanced colon cancer would benefit from a reduction in chemotherapy post-surgery, without increasing risk of recurrence, to reduce risk of neuropathy.

According to findings reported at ASCO 2017, patients receiving treatment for metastatic cancer who used a web-based tool to report their symptoms lived on average 5 months longer.

According to findings presented at 2017 ASCO, frontline treatment with ribociclib (Kisqali) plus letrozole improved PFS for patients with HR+/HER2- advanced breast cancer.

As presented at ASCO 2017, a recent study found that psychological intervention can substantially lower the fear of cancer recurrence in survivors.

A recent survey found that women with ovarian cancer are uncertain of what to expect, and experience a gap when communicating with healthcare providers.

The Bladder Cancer Advocacy Network (BCAN) announced the recipients of the 2017 Young Investigator Awards.

The traditional Chinese exercise, tai chi, may assist breast cancer survivors experiencing insomnia.

A recent study found that gliomas are less common among patients with higher blood sugar and diabetes.

A form of T-cell (non-Hodgkin) lymphoma known as breast implant associated anaplastic large-cell lymphoma (BIA-ALCL) has been noted as a rare association with the implant-based approach of reconstructive surgery post mastectomy.

The Environmental Working Group has issued published its 11th annual guide including information on beach and sport sunscreens, moisturizers and lip products containing Sun Protection Factor (SPF).

The FDA has granted approval to the second generation ALK-inhibitor, ceritinib for treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC).

A recent study provides more evidence toward the link between electronic cigarette use and bladder cancer risk.

IBM Watson Health, Cota and Hackensack Meridian Health have joined together to help oncologists make evidence- and outcomes-based clinical decisions for their cancer patients, which could reduce total cost of care.

Pembrolizumab (Keytruda) has been granted accelerated approval for certain solid tumors.

Members of the ACCC have created an online course, Financial Advocacy Boot Camp, to help financial navigators find the funds for their patients.

Overall survival for patient with cutaneous melanoma was significantly lower for non-white patients, indicating a need for more emphasis on screening and awareness in these populations.

More Stage I cancers were diagnosed after the passage of the Affordable Care Act (ACA), also known as Obamacare, within five screenable disease types: colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer).